Invivo Therapeutics (NVIV) versus Its Rivals Critical Analysis
Invivo Therapeutics (NASDAQ: NVIV) is one of 77 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its competitors? We will compare Invivo Therapeutics to similar businesses based on the strength of its profitability, analyst recommendations, valuation, earnings, risk, institutional ownership and dividends.
Earnings & Valuation
This table compares Invivo Therapeutics and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Invivo Therapeutics||N/A||-$23.43 million||-1.03|
|Invivo Therapeutics Competitors||$2.14 billion||$234.27 million||-83.47|
Volatility and Risk
Invivo Therapeutics has a beta of 3.19, indicating that its share price is 219% more volatile than the S&P 500. Comparatively, Invivo Therapeutics’ competitors have a beta of 0.90, indicating that their average share price is 10% less volatile than the S&P 500.
Institutional and Insider Ownership
12.8% of Invivo Therapeutics shares are held by institutional investors. Comparatively, 51.8% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 3.9% of Invivo Therapeutics shares are held by company insiders. Comparatively, 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares Invivo Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Invivo Therapeutics Competitors||-322.24%||-22.32%||-8.42%|
This is a summary of recent ratings and target prices for Invivo Therapeutics and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Invivo Therapeutics Competitors||270||1853||3359||107||2.59|
Invivo Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 585.71%. As a group, “Advanced Medical Equipment & Technology” companies have a potential upside of 0.50%. Given Invivo Therapeutics’ higher probable upside, research analysts clearly believe Invivo Therapeutics is more favorable than its competitors.
Invivo Therapeutics competitors beat Invivo Therapeutics on 9 of the 12 factors compared.
About Invivo Therapeutics
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.